Patient characteristics (N = 67)
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 63 (24-82) |
| Sex, male/female | 40/27 |
| Lymphoma subcategory | |
| Follicular | 21 |
| Diffuse large | 17 |
| NHL, nonspecified | 22 |
| Other NHL | 3 |
| Hodgkin | 4 |
| Therapy before vaccination | |
| R mono | 7 |
| R-C(H)OP | 45 |
| R-ABVD | 3 |
| R-other* | 12 |
| Time, last R-dose to vaccination, d, median (range) | 21 (0-171) |
| Treatment (primary/salvage) | 41/26 |
| No. of therapy cycles in latest treatment line before vaccination, median (range) | 6 (1-12) |
| Characteristic . | Value . |
|---|---|
| Median age, y (range) | 63 (24-82) |
| Sex, male/female | 40/27 |
| Lymphoma subcategory | |
| Follicular | 21 |
| Diffuse large | 17 |
| NHL, nonspecified | 22 |
| Other NHL | 3 |
| Hodgkin | 4 |
| Therapy before vaccination | |
| R mono | 7 |
| R-C(H)OP | 45 |
| R-ABVD | 3 |
| R-other* | 12 |
| Time, last R-dose to vaccination, d, median (range) | 21 (0-171) |
| Treatment (primary/salvage) | 41/26 |
| No. of therapy cycles in latest treatment line before vaccination, median (range) | 6 (1-12) |
NHL indicates non-Hodgkin lymphoma.
Other therapies included the following: VIM (3), IKE (1), IME (2), FC (1), GMALL-2002 (2), EPOCH (1), EPOCH-fludarabine (1), and bendamustine (1).